GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptahem AB (XSAT:APTA) » Definitions » EV-to-EBITDA

Aptahem AB (XSAT:APTA) EV-to-EBITDA : -1.51 (As of May. 23, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Aptahem AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aptahem AB's enterprise value is kr15.10 Mil. Aptahem AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was kr-10.01 Mil. Therefore, Aptahem AB's EV-to-EBITDA for today is -1.51.

The historical rank and industry rank for Aptahem AB's EV-to-EBITDA or its related term are showing as below:

XSAT:APTA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -9.14   Med: -2.52   Max: 0.99
Current: -1.5

During the past 10 years, the highest EV-to-EBITDA of Aptahem AB was 0.99. The lowest was -9.14. And the median was -2.52.

XSAT:APTA's EV-to-EBITDA is ranked worse than
100% of 448 companies
in the Biotechnology industry
Industry Median: 10.08 vs XSAT:APTA: -1.50

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-23), Aptahem AB's stock price is kr0.027. Aptahem AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-0.054. Therefore, Aptahem AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Aptahem AB EV-to-EBITDA Historical Data

The historical data trend for Aptahem AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptahem AB EV-to-EBITDA Chart

Aptahem AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.29 -2.68 -1.47 -5.34 -2.15

Aptahem AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.34 -5.58 -3.18 -3.78 -2.15

Competitive Comparison of Aptahem AB's EV-to-EBITDA

For the Biotechnology subindustry, Aptahem AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aptahem AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptahem AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Aptahem AB's EV-to-EBITDA falls into.



Aptahem AB EV-to-EBITDA Calculation

Aptahem AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=15.098/-10.009
=-1.51

Aptahem AB's current Enterprise Value is kr15.10 Mil.
Aptahem AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-10.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aptahem AB  (XSAT:APTA) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Aptahem AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.027/-0.054
=At Loss

Aptahem AB's share price for today is kr0.027.
Aptahem AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.054.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Aptahem AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Aptahem AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptahem AB (XSAT:APTA) Business Description

Traded in Other Exchanges
N/A
Address
Norra Vallgatan 58, Malmo, SWE, 211 22
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.

Aptahem AB (XSAT:APTA) Headlines

No Headlines